Citation Impact
Citing Papers
Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
2014
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
2008
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
2011 Standout
Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab
2007
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer
2007
Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine
2010
Smarter drugs emerging in pancreatic cancer therapy
2014
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET
2008
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
2005
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
A view on drug resistance in cancer
2019 StandoutNature
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
2008 Standout
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
2016 Standout
The role of liposomes in clinical nanomedicine development. What now? Now what?
2019 Standout
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis
2008
Pancreatic cancer
2020 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Carbohydrate antigen 19‐9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine‐containing chemotherapy
2012
Lung Cancer
2008 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Head and neck cancer
2008 Standout
Pancreatic cancer
2016 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
2011
Nano based drug delivery systems: recent developments and future prospects
2018 Standout
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
2021 StandoutNobel
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
2009 Standout
Colorectal cancer
2019 Standout
Antibody therapy of cancer
2012 Standout
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
2010 Standout
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Cetuximab in advanced non-small cell lung cancer
2006
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates
2009 Standout
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
2007
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group
2008
Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: A focus on nano-albumin-bound drugs
2013
Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
2008
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Novel targets in gastric and esophageal cancer
2006
The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo
2012 Standout
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
2013 StandoutNobel
Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells
2011
Tumour-associated macrophages as treatment targets in oncology
2017 Standout
EGFR Signaling and Drug Discovery
2009
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer
2007
Hepatocellular carcinoma pathogenesis: from genes to environment
2006 Standout
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
2012
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study
2005
Radiomics: Extracting more information from medical images using advanced feature analysis
2012 Standout
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 Standout
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
2010
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
2007
Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer
2017
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy
2007
Panitumumab, a Monoclonal Anti–Epidermal Growth Factor Receptor Antibody in Colorectal Cancer: Another One or the One?
2007
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
2005
The Tumor Lysis Syndrome
2011 Standout
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
2006 Standout
Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK
2006
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
2017 Standout
Randomized phase II /III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS ‐PC Study
2015
FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab
2007
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Cetuximab-Related Tumor Lysis Syndrome in Metastatic Colon Carcinoma
2008
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
2007 Standout
Nanomedicine(s) under the Microscope
2011
Combination therapy in combating cancer
2017 Standout
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
2005
A Comprehensive Survey of Ras Mutations in Cancer
2012 Standout
Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches
2016 Standout
Targeting Signal Transduction Pathways in Colorectal Cancer—More Than Skin Deep
2005
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
2009
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2016
Evolving Treatment of Advanced Colon Cancer
2009
Analysis of nanoparticle delivery to tumours
2016 Standout
Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab
2007
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Clinical Translation of Nanomedicine
2015
Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer
2006
Works of B. Mirtsching being referenced
A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer
2011
Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin
2004
Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use
2007
Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines
2006
Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin
2004
Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy
2005
Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer
2005
A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer
2011
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
2010